• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

GLP-1

Dandelion Health Launches Clinical AI Marketplace + GLP-1 Study

by Jasmine Pennic 09/18/2024 Leave a Comment

Dandelion Health Launches Clinical AI Marketplace + GLP-1 Study

What You Should Know:  - Dandelion Health, a real-world data (RWD) and clinical AI platform, today announced findings from a study that suggests GLP-1 medications may be effective in preventing cardiovascular disease (CVD) in a significantly larger population than previously thought.  - This research, conducted using validated AI on Dandelion's newly launched Clinical AI Marketplace, opens the door for a new era of precision medicine and personalized care in cardiometabolic
Read More

Noom Launches $149 GLP-1 Weight Loss Program with Sustainable Approach

by Jasmine Pennic 09/12/2024 Leave a Comment

Noom Launches $149 GLP-1 Weight Loss Program with Sustainable Approach

What You Should Know:  - Noom, a digital healthcare company, is shaking up the weight loss industry with the launch of Noom GLP-1Rx, an innovative program offers affordable, accessible, and sustainable weight loss by combining compounded GLP-1 injections with Noom's proven behavioral change program. - Noom GLP-1Rx delivers highly efficacious medications to the door within seven days starting at $149 and pairs those powerful medications with Noom GLP-1 Companion with Muscle
Read More

OMNY Health Launches GLP-1 Data Network to Advance Research

by Jasmine Pennic 08/27/2024 Leave a Comment

OMNY Health Launches GLP-1 Data Network to Advance Research

What You Should Know:  - OMNY Health, a healthcare ecosystem specializing in data partnerships, today announced the launch of its GLP-1 data network.  - The GLP-1 data network aims to democratize access to healthcare data and empower researchers, clinicians, and life sciences companies to gain valuable insights into GLP-1 therapies. Addressing Data Gaps in GLP-1 Research Despite the growing use of GLP-1 agonists, there remains a significant lack of comprehensive data on
Read More

Heart Health in the GLP-1 Era: The Role of Remote Patient Monitoring

by Antoine Robiliard, VP of Withings Health Solutions 08/22/2024 Leave a Comment

Heart Health in the GLP-1 Era: The Role of Remote Patient Monitoring

According to the American Heart Association, nearly half of all adults in the U.S. have high blood pressure. Recent studies have suggested that effectively treating obesity with GLP-1 agonists may be key to improving overall heart health. These findings are promising — but additional study is necessary, further highlighting the need for accurate GLP-1 patient data and consistent at-home health monitoring. Healthcare providers can benefit from high-precision remote monitoring tools like
Read More

FuturHealth Combines GLP-1 Medications with Personalized Nutrition

by Jasmine Pennic 08/09/2024 Leave a Comment

FuturHealth Combines GLP-1 Medications with Personalized Nutrition

What You Should Know:  - FuturHealth, a leader in personalized weight-loss solutions launches its Custom Meal Plans. Designed to complement the growing popularity of GLP-1 medications, the new offering provides a comprehensive approach to weight management and long-term health. - As the use of GLP-1 medications surges, FuturHealth recognizes the need for a holistic approach to weight loss. By combining personalized meal plans with medication, FuturHealth aims to help individuals
Read More

Patients Demand Personalized Obesity Care, New Survey Finds

by Jasmine Pennic 08/07/2024 Leave a Comment

Patients Demand Personalized Obesity Care, New Survey Finds

What You Should Know:  - Phenomix Sciences, a precision medicine biotechnology company, released findings from a new survey revealing a growing demand for personalized obesity care.  - The survey of 475 patients explored attitudes toward weight management, treatment preferences, and information sources. Key Findings: Patients Seek Medical Guidance: A majority of respondents (66%) prefer guidance from healthcare providers to manage weight loss, highlighting the need for a
Read More

Physicians Reveals GLP-1s for Weight Loss are Overprescribed and Unsustainable

by Jasmine Pennic 08/06/2024 Leave a Comment

Physicians Reveals GLP-1s for Weight Loss are Overprescribed and Unsustainable,

What You Should Know:  - A large majority of physicians feel GLP-1s are being overprescribed, according to a new survey from Virta Health, a leader in type 2 diabetes reversal.  - The Virta Health survey was conducted in partnership with Beresford Research and included 300 primary care providers, endocrinologists, and obesity specialists across the United States sheds light on the medical community's views on the rapidly growing class of GLP-1 medications, often hailed as
Read More

Nestlé Health Science Launches Innovative GLP-1 Nutrition Platform

by Jasmine Pennic 06/25/2024 Leave a Comment

Nestlé Health Science Launches Innovative GLP-1 Nutrition Platform

What You Should Know:  - Nestlé Health Science, a global leader in nutritional science, today announced the launch of glp-1nutrition.com, a web platform designed to support individuals on their weight management journey, particularly those using GLP-1 medications. - The launch of glp-1nutrition.com reflects their ongoing commitment to empowering healthier lives through targeted nutritional guidance. GLP-1nutrition.com: Your One-Stop Shop for GLP-1 Weight Management Support The
Read More

Aranscia and SignatureRX Partner to Optimize GLP-1 Medication Use

by Jasmine Pennic 06/21/2024 Leave a Comment

Aranscia and SignatureRX Partner to Optimize GLP-1 Medication Use

What You Should Know:  - Aranscia, a leader in personalized diagnostics, and Signature RX, a prominent pharmacy supplier, announced a collaborative effort to improve the effectiveness of GLP-1 medications.  - The multi-phase partnership focuses on developing personalized treatment plans and ensuring consistent access to these crucial medications. GLP-1s: Beyond Type 2 Diabetes Glucagon-like peptide-1 receptor agonists (GLP-1s) were initially developed for type 2 diabetes
Read More

Weekly Ozempic/Wegovy Injections May Lower Kidney Failure Risk, Study Finds

by Jasmine Pennic 05/28/2024 Leave a Comment

What You Should Know:  - A new study suggests that a weekly treatment with semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, may significantly reduce the risk of kidney failure and other complications in patients with type 2 diabetes and chronic kidney disease (CKD).Find semaglutide online today. - Funded by Novo Nordisk creators of Ozempic and Wegovy semaglutide injections for diabetes management, the study published in The New England Journal of Medicine investigated
Read More

  • Previous Page
  • Go to page 1
  • Interim pages omitted …
  • Go to page 3
  • Go to page 4
  • Go to page 5
  • Go to page 6
  • Next Page

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

Aligning IT & Clinical Teams: How to Reduce Friction and Improve Communication

Most-Read

Aidoc Secures $150M to Accelerate Enterprise-Scale Clinical AI Across 2,000 Hospitals

OpenAI Launches ChatGPT for Clinicians: Free AI Documentation and Research Tool for Verified Physicians

OpenAI Launches ChatGPT for Clinicians: Free AI Documentation and Research Tool for Verified Physicians

IKS Health Acquires TruBridge for Rural EHR and RCM Solutions Expansion

IKS Health Acquires TruBridge for Rural EHR and RCM Solutions Expansion

UT Austin is Building the Nation's First 'AI-Native' Hospital, Backed by $750M

Why UT Austin is Building an ‘AI-Native’ Hospital from Scratch

The Medtech Pitch Deck Casino: Why Hype Still Wins, and How Scrutiny Could Improve Everyone’s Odds

The Casino Model: Why Medtech VCs Are Betting Billions on Unproven AI

Oracle Lays Off 539 Kansas City Employees as Focus Shifts to AI Data Centers

Oracle Lays Off 539 Kansas City Employees as Focus Shifts to AI Data Centers

SAMHSA and ONC Invest $20M in Behavioral Health IT Initiative

HHS Reverses 2024 Tech Reorganization: Why HHS Just Stripped AI and Cyber Operations Out of the ONC

How Small Medical Practices Can Build HIPAA-Aligned DevSecOps Without Enterprise Budgets

How Small Medical Practices Can Build HIPAA-Aligned DevSecOps Without Enterprise Budgets

Insilico Medicine and Eli Lilly Form $2.75B AI Drug Discovery Collaboration

Insilico Medicine and Eli Lilly Form $2.75B AI Drug Discovery Collaboration

Microsoft Copilot Health, Integrates Apple Health, Oura, and 50,000 EHRs in New AI Push

Microsoft Launches Copilot Health, Integrates Apple Health, Oura, and 50,000 EHRs in New AI Push

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |